J Immunol Methods 2002 Nov 1;269(1-2):197
Ponomarenko N, Durova O, Vorobiev I, Aleksandrova E, Telegin G, Chamborant O, Sidorik L, Suchkov S, Alekberova Z, Gnuchev N, Gabibov A.
Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, RAS, Ul. Miklukho-Maklaya, 16/10, 117997 GSP, V-437, Moscow, Russia
Most of the data accumulated through studies on natural catalytic autoantibodies indicate that production scales up markedly in pathological abnormalities.
We have previously described an increased level of DNA-hydrolyzing autoantibodies in the sera of patients with various autoimmune disorders [systemic lupus erythematosus (SLE), rheumatoid arthritis, scleroderma], HIV infection and lymphoproliferative diseases accompanied by autoimmune manifestations.
In the present study, we show that an increased level of catalytic activity of autoantibodies can be observed in the sera of autoimmune mice, thus providing a fundamental insight into the medical relevance of abzymes.
Polyclonal autoantibodies purified from sera of NZB/W, MRL-lpr/lpr and SJL/J mice show proteolytic and DNA-hydrolyzing activities, as opposed to those harvested from non-autoimmune BALB/c mice.
The expressiveness of the catalytic activity was strongly dependent on the age of the animal.
The highest levels of catalytic activity were found in the sera of mice aged between 8 and 12 months; the lowest level was typical of younger animals whose age ranged from 6 to 8 weeks.
Specific inhibition assays of the catalytic activities were performed to throw light on the nature of the abzyme activity.
Within a cohort of aging animals, a strong correlation between marked autoimmune abnormalities and levels of catalytic activities has been established.
Nonimmunized SJL/J mice revealed specific immune responses to myelin basic protein (MBP), skeletal muscle myosin (skMyo) and cardiac myosin (Myo), and highly purified antibodies from their serum show specific proteolytic attack against the target antigens.
This finding prompted us to undertake a more detailed study of specific antibody-mediated proteolysis in diseased humans.
A targeted catalytic response was originally demonstrated against MBP and Myo in multiple sclerosis and myocarditis patients, respectively.